



INSTITUTIONAL BIOSAFETY COMMITTEE

UNIVERSITY *of* WASHINGTON

Meeting Minutes

Date: Wednesday, December 16, 2020

Time: 10:00 AM – 12:00 PM

Location: Zoom

- Members Present:**
1. Thea Brabb, Comparative Medicine (*Animal Containment Expert*)
 2. Lesley Colby, Comparative Medicine (*Animal Containment Expert*)
 3. Lesley Decker, Environmental Health & Safety (*Biosafety Officer*)
 4. Richard Grant, Washington National Primate Research Center
 5. Garry Hamilton (*Community Member*)
 6. Kevin Hybiske, Allergy and Infectious Diseases
 7. David Koelle, Allergy and Infectious Diseases
 8. Stephen Libby, Laboratory Medicine (*IBC Chair*)
 9. Scott Meschke, Environmental & Occupational Health Sciences
 10. Susan Parazzoli (*Community Member*)
 11. Jason Smith, Microbiology (*IBC Vice Chair*)
 12. Paul Swenson, Seattle-King Co. Dept. of Public Health (*Community Member*)

Commonly Used Abbreviations

IBC: Institutional Biosafety Committee

BSO: Biological Safety Officer

BUA: Biological Use Authorization

BSL: biosafety level

PI: Principal Investigator

IACUC: Institutional Animal Care and Use Committee

NIH: National Institutes of Health

DURC: Dual Use Research of Concern

SOP: standard operating procedure

1. **CALL TO ORDER:** The Institutional Biosafety Committee (IBC) Chair called the meeting to order at 10:02 a.m. A quorum was present.
2. **REMINDER:** The IBC Chair reminded attendees that any notes that they retain are subject to public disclosure. A statement was also made about conflict of interest and voting on research proposals as described in the IBC Charter. This includes sharing a grant or a familial relationship.
3. **APPROVAL OF MINUTES:**
 - The IBC Chair sought a motion to approve the minutes from the November 18, 2020 meeting.
 - A member made a motion to approve the November 18, 2020 minutes. Another member seconded the motion.
 - The committee voted unanimously to approve the November 18, 2020 meeting minutes.
4. **OLD BUSINESS:**
 - At the June 17, 2020 meeting, Dr. Altemeier's BUA was approved pending review of the IACUC protocol and required training. This BUA is still pending.
 - At the August 19, 2020 meeting, Dr. Hyde's BUA was approved pending review of the IACUC submission. This BUA is still pending.
 - At the August 19, 2020 meeting, Dr. Voigt's BUA was approved pending a medical management plan, Occupational Health consultations, training, and edits to the BUA application. This BUA is still pending.
 - At the November 18, 2020 meeting, Dr. Fowler's BUA was approved pending verification of viral vector use. This BUA has been sent out.
 - At the November 18, 2020 meeting, Dr. Iritani's BUA was approved pending a successful lab inspection. This BUA has been sent out.
 - At the November 18, 2020 meeting, Dr. Murphy's BUA was approved pending a successful lab inspection. This BUA has been sent out.
 - At the November 18, 2020 meeting, Dr. Soetedjo's BUA was approved pending application edits and a successful lab inspection. This BUA has been sent out.
 - At the November 18, 2020 meeting, Dr. Zheng's BUA was approved pending a successful lab inspection. This BUA has been sent out.
5. **BIOSAFETY OFFICER (BSO) REPORT:** The Biosafety Officer Report includes (1) projects involving recombinant or synthetic nucleic acids covered under section III-E and III-F of the *NIH Guidelines*, (2) proposals involving non-recombinant biohazardous agents requiring BSL-1 and BSL-2 containment, and (3) administrative updates, such as room additions.
 - a. Biosafety Officer Report
 - Dr. Regnier added new rooms for use with previously approved agents to the BUA *Rodent Striated Muscle*.
 - Dr. Winkler added human cells and the non-recombinant human OC43 coronavirus strain to the BUA *Winkler Lab - S. aureus and waste water SARS-CoV-2 testing*.
 - Dr. Stergachis was approved for work with Escherichia coli, non-pathogenic strains in vitro on the new BUA *Single-molecule chromatin architectures of disease-associated non-coding genetic variants*.
 - Dr. Allbritton added two non-recombinant bacteria, Akkermansia muciniphila and Bacteroides thetaiotaomicron, to the BUA *Tissue culture in Allbritton Lab*.

- Dr. Gravett was approved for work with human blood, tissue, body fluids, and cell lines for the BUA *Placentomics using a novel method to isolate circulating placental derivatives*.
- Dr. Lockwood was approved for work with human blood, tissue, body fluids, and cell lines for the BUA *Genetics and Solid Tumors Laboratory*.
- Dr. Veessler added heat inactivated NHP tissues from primates experimentally infected with SARS-CoV-2 to the BUA *Expression of recombinant proteins using mammalian cell lines*. No viral isolation or culturing is permitted.
- Dr. Swisher added a new room to the BUA *Cancer Risks Associated with Inherited Mutations in Ovarian Cancer Susceptibility Genes Beyond BRCA1 and BRCA2*.
- Dr. Cookson added in vitro use of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Aspergillus brasiliensis*, *Cryptococcus albidus*, and *Toxoplasma gondii* to the BUA *Initiation and Regulation of Inflammation and Development of Protective Immunity*.
- Dr. Starita added a new lab space for work with previously approved agents to the BUA *Brotman Baty Advanced Technology Lab: General Research*.
- Dr. Gao renewed the BUA *Cryopreservation of Cells and Tissues*.
- Dr. Levitt was approved for the new BUA *Cerebrovascular pathobiology*. Work includes use of human blood, tissue, body fluids, and cell lines.
- Dr. Adams Waldofr added a new lab space to the BUA *Influenza and Coronavirus Model of Immunity in Pregnancy*.
- Dr. Curnow was approved for the new BUA *Reproductive Biology and Stem Cell Program*. Work includes creation of transgenic gerbils.
- Dr. Gulsuner renewed the BUA *Gulsuner Lab Research* working with recombinant or synthetic DNA/RNA (non-viral) – enhanced gene delivery methods.
- The IBC Chair a motion to approve this month's Biosafety Officer Report.
- A member made a motion to approve this month's Biosafety Officer Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's Biosafety Officer Report.

6. BSL-3 INACTIVATION REPORT:

- One project received approval for SARS-CoV-2 inactivation by 10% formalin.
- The IBC Chair sought a motion to approve this month's BSL-3 Inactivation Approvals Report.
- A member made a motion to approve this month's BSL-3 Inactivation Approvals Report. Another member seconded the motion.
- The Committee unanimously voted to approve this month's BSL-3 Inactivation Approvals Report.

7. **DURC REPORT:** The Dual Use Research of Concern Institutional Review Entity (DURC IRE) did not meet this month because there were no applications to review.

8. INDIVIDUAL PROJECT REVIEWS

- a. Abkowitz, Janis, renewal, *The role of FLVCR in hematopoiesis and iron homeostasis*
 - The assigned IBC Primary Reviewer presented the Primary Review.

- The goal of this study is to understand the role of heme and FLVCR in blood cell development, maintaining body iron balance, cellular homeostasis, and to develop model systems of normal and abnormal cell development.
 - Work includes use of gammaretroviral vectors in mice.
 - The committee discussed the ability of the wild type virus to infect human cells, and determined that all viruses should be listed as BSL-2 on the BUA letter.
 - A successful lab inspection is required.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Abkowitz pending BUA letter edits and a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Abkowitz pending the items above.
- b. Ceze, Luis, renewal, *King County public transport SARS-CoV-2 testing***
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This change is to add alphavirus-like particles that encapsulate RNA containing part of the SARS-CoV-2 genome for in vitro work. These are commercially available, replication-defective VLPs that can be used as positive controls for detection of SARS-CoV-2 genetic material.
 - A successful lab inspection is required.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Ceze pending a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Ceze pending a successful lab inspection.
- c. Greninger, Alex, change, *Discovery and Characterization of Virus-Host Interactions***
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This project change adds work with recombinant forms of HIV-1, HIV-2, SIV and human T-lymphotropic virus (HTLV) at BSL-2 with BSL-3 practices.
 - A successful lab inspection has been completed.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Greninger.
 - The Committee voted unanimously to approve the draft BUA for Dr. Greninger. There was one voting abstention.
- d. Sancak, Yasemin, renewal, *Role of mitochondrial calcium uptake in health and disease***
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The goal of this renewal is to investigate the role of mitochondrial calcium uptake in various biological processes and diseases.
 - Work includes in vitro use of Lentiviral vectors, third generation, non-HIV pseudotyped, replication deficient.
 - A successful lab inspection has been completed.
 - All of the required trainings have been completed.

- The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Sancak.
 - The Committee voted unanimously to approve the draft BUA for Dr. Sancak.
- e. Savan, Ram, renewal, *Gene regulation of immune genes and the effect on immune responses*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This renewal is to continue work on post-transcriptional regulatory elements involved in immune gene dosage. All work is in vitro.
 - Work includes use of Gammaretroviral vectors, replication deficient, ecotropic, Influenza A virus strains, Vesicular stomatitis virus (VSV), Indiana Strain, and Lentiviral vectors, non-HIV pseudotyped, replication deficient.
 - A successful lab inspection is required.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Savan pending a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Savan pending a successful lab inspection.
- f. Singh, Pradeep, renewal, *Determinants of virulence and antimicrobial tolerance in biofilm and acute infections*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - The goal of this renewal is to investigate how P.aeruginosa and other bacteria interact with their host and each other.
 - Work includes use of various agents at BSL-2 in mice, rats, and in vitro.
 - A successful lab inspection is required.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Singh pending a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Singh pending a successful lab inspection.
- g. Vojtech, Lucia, change, *Mechanisms of sexual virus transmission*
- The assigned IBC Primary Reviewer presented the Primary Review.
 - This change adds in vitro use of recombinant, non-antibiotic resistant, Chlamydia trachomatis strains.
 - A successful lab inspection is required.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Vojtech pending a successful lab inspection.
 - The Committee voted unanimously to approve the draft BUA for Dr. Vojtech pending a successful lab inspection.
- h. Woodward, Joshua, renewal, *Pathogenesis of Listeria monocytogenes and Staphylococcus aureus*
- The assigned IBC Primary Reviewer presented the Primary Review.

- The overall research goal is to characterize the mechanisms by which *Listeria monocytogenes* and *Staphylococcus aureus* are able to infect and replicate within their host and to define the innate immune response to infection.
- A successful lab inspection is required.
- All of the required trainings have been completed.
- The draft BUA letter was shown.
- The IBC Primary Reviewer made a motion to approve the draft BUA for Dr. Woodward pending a successful lab inspection and clarification regarding the possible addition of gammaretroviral vectors.
- The Committee voted unanimously to approve the draft BUA for Dr. Woodward pending the items above.

9. SUBCOMMITTEE REPORTS:

- i. Oberst, Andrew, change, *Programmed cell death and immunity*
 - Two members of the IBC served as the Subcommittee Reviewers. One of the Subcommittee Reviewers presented the Subcommittee Report.
 - The PI is expanding their current program to use the mouse model as a platform for assessing the roles of programmed cell death pathways in SARS-CoV-2 infection.
 - Mice will be infected with SARS-CoV-2 in the ABSL3 facility.
 - All of the required trainings have been completed.
 - The draft BUA letter was shown.
 - A member made a motion to approve the draft BUA letter for Dr. Oberst. Another member seconded the motion.
 - The Committee voted unanimously to approve the draft BUA for Dr. Oberst.

10. FOR YOUR INFORMATION:

- **Section III-F:** Section III-F approvals will now be included on BUA letters in order to capture BSL-1 lab inspections in the EHSA database.
- **Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition is now available.**

11. ISSUES FROM THE FLOOR & PUBLIC COMMENTS: There were no issues from the floor, and no public comments.

12. MEETING ADJOURNED AT APPROXIMATELY 11:28 A.M.